Press Releases July 30, 2026 05:30 PM

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

Seer Receives Revised Acquisition Proposals from Radoff-JEC Group and CEO Omid Farokhzad

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer, Inc., a Nasdaq-listed proteomics company, announced receipt of further revised unsolicited acquisition proposals from both the Radoff-JEC Group and its CEO, Omid Farokhzad, for all outstanding shares priced around $2.45 to $2.55 per share plus contingent value rights. The Special Committee of Seer's Board will review these bids and other alternatives to determine the best course of action for shareholders.

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Seer received two revised, unsolicited, non-binding acquisition proposals for its Class A common stock from the Radoff-JEC Group and CEO Omid Farokhzad.
  • Proposals include cash offers around $2.45 to $2.55 per share along with contingent value rights, indicating potential additional future payments.
  • Seer's Special Committee is actively reviewing these proposals to determine the best interests of the company and its stockholders.
  • Sectors impacted include biotechnology, healthcare, and financial markets due to potential change of control in a proteomics tech firm.

REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right.

On July 29, 2026, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights. The full text of the letter received from Dr. Farokhzad outlining his revised proposal will be included in a Form 8-K filing made by Seer.

The previously constituted Special Committee of Seer’s Board of Directors, in consultation with its advisors, will carefully review and consider both proposals, as well as other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and all Seer stockholders.

No stockholder action is required at this time.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at [email protected].

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions of the Special Committee. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
[email protected]

Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449


Risks

  • Uncertainty whether either proposal will lead to an acquisition or if a better offer might emerge, potentially delaying clarity for investors.
  • Contingent value rights tied to these offers introduce risk regarding future payments and their realization.
  • If the acquisition attempts face regulatory, shareholder approval, or financing challenges, it could prolong the process and affect stock volatility, impacting biotech and healthcare investors.

More from Press Releases

Telix H1 2026 Results: Investor Webcast Notification Jul 30, 2026 Inno Holdings Inc. Updates Trading Time for the Resumption of Trading on Nasdaq Jul 30, 2026 OceanFirst Financial Corp. Announces Second Quarter Financial Results Jul 30, 2026 Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma Jul 30, 2026 Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results Jul 30, 2026